CLAIMS

What is claimed is:

1. Use of an extract composition of fruiting body of Antrodia in the manufacture of a medicament of the treatment of bone marrow suppression caused by a drug, wherein the bone marrow suppression comprises low number of red blood cells and/or thrombocytopenia, wherein the extract composition of fruiting body of Antrodia comprises a supercritical carbon dioxide fluid extract of fruiting body of Antrodia, which is obtained by extracting the fruiting body of Antrodia with supercritical carbon dioxide fluid, concentrating with a simulated moving bed and C18 solid adsorbent, and collecting a portion with Henry constant of more than 2.8; and wherein the drug is cyclophosphamide.

2. The use according to claim 1, wherein the supercritical carbon dioxide fluid extract of fruiting body of Antrodia is obtained by extracting the fruiting body of Antrodia at a pressure of 150 bar to 1000 bar and at a temperature of 25°C to 80°C.

3. The use according to claim 1, wherein the drug is for treating tumor selected from the group consisting of malignant lymphoma, Wilm's tumor, head and neck squamous cell carcinoma, bone cancer, hypercalcemia associated with bone metastasis lesions and testicular cancer.

4. The use according to claim 1, wherein the drug is selected from the group consisting of chlorambucil, cytarabine, dactinomycin, bleomycin, pilcamycin, etoposide, nitrosourea, and cyclophosphamid.

5. The use according to claim 1, wherein the extract composition of fruiting body of Antrodia further comprises a sesame extract, wherein the sesame extract comprises a supercritical carbon dioxide fluid extract of sesame.

6. The use according to any of claims 1 to 5, which is in the manufacture of a

medicament of the treatment of bone marrow suppression comprising low number of red blood cells and/or thrombocytopenia complicated with low number of white blood cells.

7. The use according to claim 6, which is in the manufacture of a medicament of increasing the total number of white blood cells, increasing the number of granulocytes, increasing the number of neutrophils, increasing the number of lymphocytes, increasing the number of monocytes and/or promoting granulocyte-macrophage colony-stimulating factor secretion.

8. The use according to any of claims 1 to 5, which is in the manufacture of a medicament of the treatment of bone marrow suppression comprising low number of red blood cells and/or thrombocytopenia complicated with body weight loss.